Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-10-02
2010-10-12
Stockton, Laura L. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S301000
Reexamination Certificate
active
07812167
ABSTRACT:
Compounds of the formulain-line-formulae description="In-line Formulae" end="lead"?R—NH-Q (I)in-line-formulae description="In-line Formulae" end="tail"?provide pharmacological agents which are glucokinase activators and thus may be employed for the treatment of glucokinase mediated conditions. Accordingly, the compounds of formula (I) may be employed for prevention and treatment of impaired glucose tolerance, Type 2 diabetes and obesity.
REFERENCES:
patent: 6320050 (2001-11-01), Bizzarro et al.
patent: 6353111 (2002-03-01), Corbett et al.
patent: 6369232 (2002-04-01), Sidduri
patent: 6384220 (2002-05-01), Corbett et al.
patent: 6388071 (2002-05-01), Mahaney
patent: 6388088 (2002-05-01), Sidduri
patent: 6433188 (2002-08-01), Corbett et al.
patent: 6441184 (2002-08-01), Corbett et al.
patent: 6448399 (2002-09-01), Corbett et al.
patent: 6486184 (2002-11-01), Kester et al.
patent: 6489485 (2002-12-01), Bizzarro et al.
patent: 6528543 (2003-03-01), Bizzarro et al.
patent: 6545155 (2003-04-01), Corbett et al.
patent: 6583288 (2003-06-01), Goodnow et al.
patent: 6608218 (2003-08-01), Kester et al.
patent: 6610846 (2003-08-01), Bizzarro et al.
patent: 6784298 (2004-08-01), Goodnow et al.
patent: 2001/0039344 (2001-11-01), Bizzarro et al.
patent: 2001/0051731 (2001-12-01), Bizzarro et al.
patent: 2001/0053851 (2001-12-01), Mahaney
patent: 2001/0056191 (2001-12-01), Goodnow et al.
patent: 2002/0035266 (2002-03-01), Sidduri
patent: 2002/0035267 (2002-03-01), Sidduri
patent: 2002/0042512 (2002-04-01), Kester et al.
patent: 2002/0082260 (2002-06-01), Guertin
patent: 2002/0103241 (2002-08-01), Corbett et al.
patent: 2002/0107396 (2002-08-01), Corbett et al.
patent: 2002/0198200 (2002-12-01), Kester et al.
patent: 2003/0219887 (2003-11-01), Corbett et al.
patent: 2003/0225283 (2003-12-01), Corbett et al.
patent: 2003/0225286 (2003-12-01), Goodnow et al.
patent: 2004/0014968 (2004-01-01), Bizzarro et al.
patent: 2004/0067939 (2004-04-01), Corbett
patent: 2004/0147748 (2004-07-01), Chen et al.
patent: 2004/0186290 (2004-09-01), Fyfe et al.
patent: 2007/0265297 (2007-11-01), Bebernitz
patent: 2008/0103167 (2008-05-01), Bebernitz
patent: 2008/0312256 (2008-12-01), Bebernitz
patent: 2008/0318948 (2008-12-01), Bebernitz
patent: 10259786 (2003-07-01), None
patent: 1 532 980 (2003-11-01), None
patent: 2385328 (2003-08-01), None
patent: WO 00/58293 (2000-10-01), None
patent: 0144216 (2001-06-01), None
patent: 0183478 (2001-11-01), None
patent: WO 01/ 83465 (2001-11-01), None
patent: WO 01 85706 (2001-11-01), None
patent: WO 01 85707 (2001-11-01), None
patent: WO 02 08209 (2002-01-01), None
patent: WO 02/14312 (2002-02-01), None
patent: 0248106 (2002-06-01), None
patent: WO 02/46173 (2002-06-01), None
patent: WO 03/000262 (2003-01-01), None
patent: 03015774 (2003-02-01), None
patent: WO 03/015774 (2003-02-01), None
patent: WO 03/047626 (2003-06-01), None
patent: WO 03/055482 (2003-07-01), None
patent: 03080585 (2003-10-01), None
patent: 03097824 (2003-11-01), None
patent: WO 03/095438 (2003-11-01), None
patent: 2004002481 (2004-01-01), None
patent: WO 2004/002481 (2004-01-01), None
patent: 2004050645 (2004-06-01), None
patent: WO 2004/052869 (2004-06-01), None
patent: 2004063179 (2004-07-01), None
patent: 2004063194 (2004-07-01), None
patent: 2004072066 (2004-08-01), None
patent: WO 2004/072031 (2004-08-01), None
patent: 2004076420 (2004-09-01), None
patent: 2004081001 (2004-09-01), None
patent: 2005095417 (2005-10-01), None
patent: 2005095418 (2005-10-01), None
patent: 2005103021 (2005-11-01), None
patent: 2006016194 (2006-02-01), None
patent: 2006058923 (2006-06-01), None
patent: 2007041365 (2007-04-01), None
patent: 2007041366 (2007-04-01), None
CA 62:11850, 1965.
.Colagiuri et al., American Journal of Public Health, Sep. 2006, vol. 96, No. 9, pp. 1562-1569.
Bruno et al., Expert Opinion Emerging Drugs, (2005), 10(4), pp. 747-771.
Park, Diabetes Research and Clinical Practice 66S (2004), S33-S35.
Curtis et al.,The Journal of the American Board of Family Practice, vol. 18, pp. 37-43, (2005).
Brocklehurst, K. et al., “Stimulation of Hepatocyte Glucose Metabolism by Novel Small Molecule glucokinase Activators”, Diabetes, vol. 53, pp. 535-541, Mar. 2004.
Castelhano, A. et al., “Glucokinase-activating Ureas”, Bioorg. Med. Chem. Lett., vol. 15, pp. 1501-1504 (2005).
Grimsby, J. et al., “Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy”, Science, vol. 301, pp. 370-373, Jul. 18, 2003.
Leighton, B. et al., “Small Molecule glucokinase activators as novel anti-diabetic agents”, Chemical Society Transactions, vol. 33, part 2, pp. 371-374 (2005).
McKerrecher, D. et al., “Discovery, synthesis and biological evaluation of novel glucokinase activators”, Bioorganic & Medicinal Chemistry Letters, vol. 15, pp. 2103-2106 (2005).
Otaegul, P. et al., “Glucose-Regulated Glucose Uptake by Transplanted Muscle Cells Expressing Glucokinase Counteracts Diabetic Hyperglycemia”, Human Gene Therapy, vol. 13, pp. 2125-2133 (Dec. 10, 2002).
Sarabu, et al.: “Targeting glucokinase activation for the treatment of type 2 diabetes—A status review,” Current Opinion in Drug Discovery & Development 2005 8(5):631-637.
Guertin et al., “Small Molecule Glucokinase Activators as Glucose Lowering Agents: A New Paradigm for Diabetes Therapy” Current Medicinal Chemistry 13:1839-1843 (2006).
Coope et al., “Predictive blood glucose lowering efficacy by Glucokinase activators in high fat fed female Zucker rats” British Journal of Pharmacology:1-8 (2006).
Printz, et al., “Tweaking the Glucose Sensor: Adjusting Glucokinase Activity with Activator Compounds” Endocrinology 146(9):3693-3695 (Sep. 2005).
Futamura et al., “An Allosteric Activator of Glucokinase Impairs the Interaction of Glucokinase and Glucokinase Regulatory Protein and Regulates Glucose Metabolism,” The Journal of Biological Chemistry, Manuscript M605186200 (Oct. 6, 2006).
McKerrecher et al., “Design of a potent, soluble glucokinase activator with excellent in vivo efficacy” Bioorganic & Medicinal Chemistry Letters (2006).
Grimsby, “Discovery and Actions of Glucokinase Activators” Metabolic Diseases World Summit, Jul. 24-25, 2006.
Efanov et al., “A novel glucokinase activator modulates pancreatic islet and hepacyte function” Endocrinology (May 26, 2005).
Matschinsky et al., “The Network of Glucokinase-Expressing Cells in Glucose Homeostasis and the Potential of Glucokinase Activators for Diabetes Therapy” Diabetes 55:1-12 (Jan. 2006).
Office Action mailed in U.S. Patent Application Publication No. 2007-0265297 (U.S. Appl. No. 11/547,227) on Apr. 7, 2009.
Office Action mailed in U.S. Patent Application Publication No. 2008-0103167 (U.S. Appl. No. 11/547,046) on Dec. 19, 2008.
Office Action mailed in U.S. Patent Application Publication No. 2008-0318948 (U.S. Appl. No. 12/088,608) on Sep. 14, 2009.
Devlin Theresa
Novartis AG
Stockton Laura L.
LandOfFree
Substituted (thiazol-2-yl)-amides or sulfonamides as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted (thiazol-2-yl)-amides or sulfonamides as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted (thiazol-2-yl)-amides or sulfonamides as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4158706